Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G F Cleland

Showing results (1-10 of 745) with videos related to

Pageof 75
Sort By:
European Journal of Heart Failure|May 30, 2002
How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journeyJohn G F Cleland
Progress in Cardiovascular Diseases|May 15, 2002
Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular diseaseJohn G F Cleland
Thrombosis and Haemostasis|January 20, 2022
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?John G F Cleland
European Journal of Heart Failure|December 13, 2016
Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!John G F Cleland
Heart Rhythm|May 1, 2025
An iconic figure from CARE-HF: The Cardiac Resynchronization - Heart Failure trialJohn G F Cleland
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 19, 2005
Patients with treatable malignant diseases--including heart failure--are entitled to specialist careJohn G F Cleland
BMJ (Clinical Research Ed.)|November 21, 2008
POPADAD trial. Time for a proper study of aspirin after a vascular event?John G F Cleland
BMJ (Clinical Research Ed.)|February 2, 2002
Chronic aspirin is effective--if data are massaged sufficientlyJohn G F Cleland
The Medical Clinics of North America|April 16, 2003
Beta-blockers for heart failure: why, which, when, and whereJohn G F Cleland
The American Journal of Medicine|January 25, 2012
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular diseaseJohn G F Cleland
Pageof 75

Showing results (1-10 of 745) with videos related to

Sort By:
Pageof 75
European Journal of Heart Failure|May 30, 2002
How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journeyJohn G F Cleland
Progress in Cardiovascular Diseases|May 15, 2002
Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular diseaseJohn G F Cleland
Thrombosis and Haemostasis|January 20, 2022
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?John G F Cleland
European Journal of Heart Failure|December 13, 2016
Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!John G F Cleland
Heart Rhythm|May 1, 2025
An iconic figure from CARE-HF: The Cardiac Resynchronization - Heart Failure trialJohn G F Cleland
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 19, 2005
Patients with treatable malignant diseases--including heart failure--are entitled to specialist careJohn G F Cleland
BMJ (Clinical Research Ed.)|November 21, 2008
POPADAD trial. Time for a proper study of aspirin after a vascular event?John G F Cleland
BMJ (Clinical Research Ed.)|February 2, 2002
Chronic aspirin is effective--if data are massaged sufficientlyJohn G F Cleland
The Medical Clinics of North America|April 16, 2003
Beta-blockers for heart failure: why, which, when, and whereJohn G F Cleland
The American Journal of Medicine|January 25, 2012
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular diseaseJohn G F Cleland
Pageof 75